The aim of this study is to define the putative role of complement activation and mucosal mast cell (MMC) degranulation in the pathogenesis of rapid ischemia-reperfusion (I/R) injury. We prepared complement activity-depleted rats by the administration of the anti-complementary agent K-76COONa. To assess the role of MMC degranulation, we used the MMC stabilizer MAR-99 and genetically mast cell-deficient Ws/Ws rats. Autoperfused segments of the jejunum were exposed to 60 min of ischemia, followed by 60 min reperfusion. The epithelial permeability was assessed by 51Cr-EDTA clearance rate, and the number of MMC was immunohistochemically assessed. I/R treatment induced a marked increase in mucosal permeability and MMC degranulation. The treatment with K-76COONa and MAR-99 significantly attenuated these changes. Furthermore, in Ws/Ws rats the increase in mucosal permeability and MMC degranulation was significantly attenuated. These findings indicate the role of complement activation and MMC activation in the pathogenesis of rapid intestinal I/R injury. A regulation of the complement activation and MMC degranulation may be one of the clinical strategies for prevention of I/R-induced mucosal injury.

01 Aug 1998·European journal of gastroenterology & hepatologyQ4 · MEDICINE

The role of mucosal mast cell degranulation and free-radical generation in intestinal ischaemia-reperfusion injury in rats.

Q4 · MEDICINE

Article

Author: Bamba, T ; Fujiyama, Y ; Sasaki, M ; Andoh, A ; Fukuda, M ; Nakajima, S ; Kimura, T

OBJECTIVESIn this study, we determined the role of mucosal mast cell (MMC) activation in the pathogenesis of intestinal ischaemia-reperfusion (I/R) injury by immunohistochemical analysis using anti-RMCP II antibody. In addition, we investigated the role of free-radical generation in the activation of MMCs in this model.METHODSIn the first experiment, rats were divided into four groups: (1) sham operated; (2) I/R + saline; (3) I/R + the mast cell stabilizer, MAR-99 (30 mg/kg); and (4) I/R + MAR-99 (100 mg/kg). Treatment with MAR-99 was started 1 h before the occlusion of the superior mesenteric artery (SMA). In the second experiment, rats were divided into five groups: (1) sham operated; (2) I/R + saline; (3) I/R + superoxide dismutase (SOD; 50,000 U/ml); (4) I/R + catalase (90,000 U/ml); and (5) I/R + allopurinol (50 mg/kg/day). Intravenous administration of SOD and catalase was performed 1 h before SMA occlusion. Oral administration of allopurinol was started 2 days before I/R surgery. We measured several parameters of intestinal mucosal injury and evaluated the degranulation of MMCs by using an immunohistochemical technique.RESULTSThe number of resting MMCs, detected by anti-RMCP II antibody, was significantly decreased in the I/R-treated rats. The I/R treatment induced a decrease in the mucosal histamine content and an increase in plasma histamine levels. Mucosal permeability in the small intestine was significantly enhanced by I/R treatment. However, these changes were significantly prevented by pretreatment with the MMC stabilizer, MAR-99. Furthermore, administration of several free-radicals scavengers (SOD, catalase, and allopurinol) also blocked the I/R-induced degranulation of MMCs.CONCLUSIONThese data indicate that activation of MMCs was involved in the pathogenesis of I/R-induced intestinal mucosal injury. In addition, some parts of the I/R-induced MMC activation pathway were mediated by free-radical generation.

01 Sep 1996·Arzneimittel-Forschung

Anti-gastric acid secretory mechanism of 1,6-dihydro-2-[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidinecarboxylic acid. Effect on mucosal mast cell.

Article

Author: Sato, M ; Ishizuka, Y ; Kamisaki, T

To clarify the anti-gastric acid secretory mechanism of 1,6-dihydro-2-[2-(2-methylpropoxy)anilino]-6-oxo-5-pyrimidinecarbo xylic acid (CAS 98772-05-5, MAR-99), the relationship between gastric acid secretion and gastric mucosal mast cell (MMC) was studied and the effect of this compound on these parameters was examined and compared with anti-allergic drugs (mast cell stabilizers) and anti-ulcer drugs. The release of histamine from MMC cultured from bone marrow and connective tissue mast cell (CTMC) isolated from peritoneal cavity was found to be induced by the addition of ethanol (final conc. 17.5%), and the inhibitory effect on histamine release from MMC is closely associated with the anti-gastric secretory effect. That is to say, MAR-99 (10(-9)-10(-7) mol/l) inhibited histamine release from MMC induced by ethanol in a concentration-dependent manner. The action of MAR-99 on MMC was more sensitive than that of CTMC. In addition, MAR-99 (100 mg/kg i.d.) suppressed gastric acid secretion. On the other hand, anti-allergic drugs (mast cell stabilizers), such as DSCG and tranilast (both 10(-7) mol/l), markedly inhibited histamine release from CTMC induced by ethanol, but these drugs (10(-8)-10(-7) mol/l) showed only a tendency to prevent the release of histamine from MMC. Furthermore these drugs (both 100 mg/ kg i.d.) had no effects on gastric acid secretion. Equally anti-ulcer drugs, such as cetraxate, teprenone and sofalcone, had no effects on histamine release from mast cells of two types and gastric acid secretion. From these results, it was suggested that MMC is closely correlated with gastric acid secretion, and the anti-gastric secretory effect of MAR-99 may mainly contribute to prevent the degranulation of MMC.

100 Deals associated with MAR-99

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Discovery	JP	EA Pharma Co., Ltd.	-
Stomach Ulcer	Discovery	JP	EA Pharma Co., Ltd.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

MAR-99

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation